<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088178</url>
  </required_header>
  <id_info>
    <org_study_id>NMCP.2009.0062</org_study_id>
    <nct_id>NCT01088178</nct_id>
  </id_info>
  <brief_title>Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period</brief_title>
  <official_title>Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period: A Prospective, Randomized Pilot Study of Three Time Intervals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Naval Medical Center, Portsmouth</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United States Naval Medical Center, Portsmouth</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators study is a prospective randomized trial of women undergoing the
      levonorgestrel intrauterine system (LNG-IUS: Mirena©, Bayer) at three separate time periods:
      immediate post placental (IPP) defined as insertion within 10 min delivery of placenta, early
      post partum (EP) defined as insertion after 10 min but within 72hrs postpartum, or interval
      (INT) insertion defined as insertion after 6wks postpartum. This is a pilot study in
      preparation for a multicenter, prospective randomized study of long-acting reversible
      contraception in the postpartum period.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuation Rates of the LNG-IUS when placed postpartum at three time periods</measure>
    <time_frame>at 6 months</time_frame>
    <description>Determine if there is a difference in continuation rates at 6 months between participants who had the LNG-IUS placed at three different time periods: Immediate Postplacental (within 10 minutes from delivery of placenta), Early Postpartum (after 10 minutes but before 48 hours postpartum) , and Interval (after 6 weeks postpartum).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expulsion rate of the LNG-IUS when placed postpartum at three time periods</measure>
    <time_frame>at 3 weeks</time_frame>
    <description>Determine if there is a difference in expulsion rates at the three different time periods of placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at placement</measure>
    <time_frame>at 1 minute</time_frame>
    <description>Determine if there is a difference pain as assessed with the Visual Analog Scale at the time of placement of the LNG-IUS at three time period: Immediate Postplacental, Early Postpartum, or Interval.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Immediate Postplacental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 10 minutes from delivery of placenta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Postpartum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 10 minutes from delivery of placenta but within 48hrs from delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 6 weeks postpartum</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)</intervention_name>
    <description>Placement of Mirena at given intervals during the postpartum period</description>
    <arm_group_label>Immediate Postplacental</arm_group_label>
    <arm_group_label>Early Postpartum</arm_group_label>
    <arm_group_label>Interval</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All reproductive age women who express a desire for the LNG-IUS (Mirena©) at routine
             questioning at their 36-38 week prenatal appointment or upon admission to labor and
             delivery are eligible for our study.

        Exclusion Criteria:

          -  Contraindications to the LNG-IUS include: Pregnancy or suspicion of pregnancy,
             Congenital or acquired uterine anomaly including fibroids if they distort the uterine
             cavity, Postpartum endometritis within the past 3 months, Known or suspected uterine
             or cervical neoplasia or unresolved, abnormal pap smear, untreated acute cervicitis or
             vaginitis including bacterial vaginosis or other lower genital tract infections, acute
             liver disease or liver tumor, hypersensitivity to any component of the product, known
             or suspected carcinoma of the breast. Any of these conditions would exclude the
             patient from our study.

          -  Delivery &lt;36 weeks

          -  Intrapartum chorioamnionitis (defined as maternal fever &gt;100.4 and two of the
             following conditions: Maternal leukocytosis (greater than 15,000 cells/cubic
             millimeter), Maternal tachycardia (greater than 100 beats/minute), Fetal tachycardia
             (greater than 160 beats/minute), Uterine tenderness, Foul odor of the amniotic fluid

          -  Postpartum Hemorrhage (defined as &gt;500cc EBL for spontaneous vaginal delivery)

          -  Cesarean delivery if randomized to IPP or EP placement
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joshua D Dahlke, MD</last_name>
    <phone>757-953-4503</phone>
    <email>joshua.dahlke@med.navy.mil</email>
  </overall_contact>
  <location>
    <facility>
      <name>Naval Medical Center</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua D Dahlke, MD</last_name>
      <email>joshua.dahlke@med.navy.mil</email>
    </contact>
    <investigator>
      <last_name>Joshua D Dahlke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>September 29, 2010</last_update_submitted>
  <last_update_submitted_qc>September 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>LCDR Joshua D. Dahlke MD</name_title>
    <organization>Naval Medical Center Portsmouth Virginia</organization>
  </responsible_party>
  <keyword>Long-Acting Reversible Contraception</keyword>
  <keyword>Contraceptive Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Contraceptive Agents, Female</keyword>
  <keyword>Reproductive Control Agents</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Levonorgestrel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

